View older revisions Content changed at 2023-01-11, 1401/10/21

Protocol summary

Study aim
Determining the effect of Aniseed oral powder on clinical improvement of gastrointestinal symptoms in patients with COVID-19
Design
Clinical trial with control group, parallel group trial, single-blinded, phase 3 on 225 patients (45 patients in the intervention group and 180 patients in the control group). Replacement randomization was used.
Settings and conduct
COVID-19 positive rapid test or RT-PCR patients admitted to Motahari Clinic of Shiraz will be divided into two groups of intervention and control. The present study will be single-blind so that patients and physicians will be unaware of how the intervention and control groups assigned.
Participants/Inclusion and exclusion criteria
Patients with COVID-19 positive rapid test or RT-PCR; aged 18 to 70 years with gastrointestinal symptoms
Intervention groups
Intervention group: Iranian standard treatment protocol for COVID-19 in addition to aniseed oral powder formulated in Shiraz University of Medical Sciences for 2 weeks. Control group: the standard treatment protocol of COVID-19 in Iran.
Main outcome variables
gastrointestinal symptoms in patients with COVID-19

General information

Reason for update
Adding achieved recruitment start and end date
Acronym
IRCT registration information
IRCT registration number: IRCT20120506009651N3
Registration date: 2022-04-04, 1401/01/15
Registration timing: prospective

Last update: 2023-01-11, 1401/10/21
Update count: 2
Registration date
2022-04-04, 1401/01/15
Registrant information
Name
Maryam Mosaffa-Jahromi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 71 3208 4030
Email address
mosaffam@sums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2022-03-26, 1401/01/06
Expected recruitment end date
2022-09-28, 1401/07/06
Actual recruitment start date
2022-05-01, 1401/02/11
Actual recruitment end date
2022-08-01, 1401/05/10
Trial completion date
2022-08-01, 1401/05/10
Scientific title
Efficacy of Aniseed powder formulation (Aniseed Safoof) to improve gastrointestinal symptoms in COVID-19 patients
Public title
Effect of Aniseed in treatment of gastrointestinal symptoms in Coronavirus disease
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Patients from 18 years old to 70 years old with a diagnosis of Coronavirus based on clinical and laboratory symptoms; hospitalization, home quarantine and outpatients Diarrhea, anorexia, nausea or vomiting and abdominal pain within 24-48 hr
Exclusion criteria:
Pregnant or nursing females Organic disorders with survival time of less than 3 days Significant allergic reactions to the herbal drug
Age
From 18 years old to 70 years old
Gender
Both
Phase
3
Groups that have been masked
  • Outcome assessor
  • Data analyser
Sample size
Target sample size: 225
Actual sample size reached: 225
Randomization (investigator's opinion)
Randomized
Randomization description
In this study, we will use the Restricted randomization method of block randomization. Blockage is usually used to balance the number of samples allocated to each of the studied groups. This feature helps researchers to equalize the number of samples allocated to each of the studied groups in cases where intermediate analyzes are required during the sampling process. All blocks are the same size, and in this two-group experiment we will have 4 blocks (including 1 participants in the intervention group and 3 participants in the control group). Random allocation software is also used to randomize random sequence production software (Random allocation software). To conceal, we use Allocation concealment, which refers to the method used to perform a random sequence on study participants, so that the assigned group is not identified before the individual is assigned. Using non-transparent envelopes sealed with random sequences (Sequentially numbered, sealed, opaque envelopes). They are placed in order. In order to maintain the random sequence, numbering is done on the outer surface of the envelopes in the same way. Finally, the lids of the letter envelopes are glued and placed inside a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants in the study, one of the envelopes of the letter will be opened in order and the assigned group of the participant will be revealed.
Blinding (investigator's opinion)
Single blinded
Blinding description
The assessor and data analyst will be blind to the random assignment of patients in groups.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee, Shiraz University of Medical Sciences
Street address
7th floor, Shiraz University of Medical Sciences, Zand street
City
Shiraz
Province
Fars
Postal code
7134814336
Approval date
2022-03-02, 1400/12/11
Ethics committee reference number
IR.SUMS.REC.1400.859

Health conditions studied

1

Description of health condition studied
COVID-19 infection
ICD-10 code
U07.1
ICD-10 code description
Covid-19, confirmed cases, positive test result

Primary outcomes

1

Description
Diarrhea
Timepoint
Before and after intervention
Method of measurement
Visual analogue scale (VAS) questionnaire which graded from zero (no sign) to 10 (severe sign).

2

Description
Anorexia
Timepoint
Before and after intervention
Method of measurement
Visual analogue scale (VAS) questionnaire which graded from zero (no sign) to 10 (severe sign).

3

Description
Abdominal pain
Timepoint
Before and after intervention
Method of measurement
Visual analogue scale (VAS) questionnaire which graded from zero (no sign) to 10 (severe sign).

Secondary outcomes

1

Description
Gastrointestinal disorders
Timepoint
End of Treatment (2 weeks after starting intervention)
Method of measurement
Visual analogue scale (VAS) questionnaire

Intervention groups

1

Description
Intervention group: Anise edible powder or anise safoof is a combination of anise fruit powder and candy powder. The method of preparation of this drug form is by grinding & sieving techniques and after grinding the components of the formula with the electric mill of Ultra Centrifugal Mill to deliver the drug to the gastrointestinal tract efficiently. This oral powder is formulated in the form of 5 g sachets in the Pharmaceutics Laboratory of Shiraz School of Pharmacy and enters the clinical phase after confirmation of physicochemical and microbial pharmacopoeia tests from the central laboratory of Shiraz University of Medical Sciences. In the clinical phase and at the beginning of the study, patients in the intervention group are instructed to drink the contents of one sachet of anise powder with a glass of water twice a day for two weeks, in addition to the usual treatment protocol. Gastrointestinal symptoms will be recorded at the beginning of the study and before the start of treatment, and during two weeks the response to treatment, including improvement or reduction of gastrointestinal symptoms, diarrhea, anorexia, nausea and abdominal pain compared to the pre-treatment status in each patient is assessed.
Category
Treatment - Drugs

2

Description
Control group: For 2 weeks, no intervention will be performed on patients in the control group except for the usual treatment protocol. Gastrointestinal symptoms are recorded at the beginning of the study and before treatment, and during two weeks, response to treatment, including improvement or reduction of gastrointestinal symptoms, diarrhea, anorexia, nausea, and abdominal pain, is assessed relative to the pre-treatment status in each patient.
Category
Other

Recruitment centers

1

Recruitment center
Name of recruitment center
Motahari Clinic
Full name of responsible person
Dr. Maryam Mosaffa-Jahromi
Street address
Namāzī, Karim Khan Zand Blvd
City
Shiraz
Province
Fars
Postal code
7193613111
Phone
+98 71 3208 4030
Fax
+98 71 3233 8476
Email
mosaffam@sums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Dr. Mehdi Pasalar
Street address
Research Center for Traditional Medicine and History of Medicine, School of Medicine, Zand Avenue
City
Shiraz
Province
Fars
Postal code
7134845794
Phone
+98 71 3208 4030
Fax
+98 71 3233 8476
Email
pasalar@sums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shiraz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Dr. Mehdi Pasalar
Position
Assistant Professor
Latest degree
Ph.D.
Other areas of specialty/work
Traditional Medicine
Street address
Research Center for Traditional Medicine and History of Medicine, School of Medicine, Zand Avenue
City
Shiraz
Province
Fars
Postal code
7134845794
Phone
009832084029
Fax
+98 71 3233 8476
Email
pasalar@sums.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Dr. Maryam Mosaffa-Jahromi
Position
Researcher
Latest degree
Ph.D.
Other areas of specialty/work
PhD in Traditional Pharmacy
Street address
Research Center for Traditional Medicine and History of Medicine, School of Medicine, Zand Avenue
City
Shiraz
Province
Fars
Postal code
7134845794
Phone
009832084037
Email
mosaffam@sums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Shiraz University of Medical Sciences
Full name of responsible person
Dr. Maryam Mosaffa-Jahromi
Position
Researcher
Latest degree
Ph.D.
Other areas of specialty/work
PhD in Traditional Pharmacy
Street address
Research Center for Traditional Medicine and History of Medicine, School of Medicine, Zand Avenue
City
Shiraz
Province
Fars
Postal code
7134845794
Phone
009832084037
Email
mosaffam@sums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...